-
Posted by
Two Blokes Jun 9 -
Filed in
Stock
-
5 views
Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results.
